Exogenus leads €13m EU consortium to advance secretome therapy
Exogenus Therapeutics is coordinating ExoCordOA, a five-year, €13 million Horizon Europe-funded consortium to advance extracellular vesicle-enriched secretome therapies with an initial focus on osteoarthritis. The consortium brings together ten organisations, including Lonza, Anthony Nolan, Eliquent
<p>Exogenus Therapeutics is coordinating ExoCordOA, a five-year, €13 million Horizon Europe-funded consortium to advance extracellular vesicle-enriched secretome therapies with an initial focus on osteoarthritis. The consortium brings together ten organisations, including Lonza, Anthony Nolan, Eliquent</p>